Key Considerations for Targeting KRAS in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
New KRAS inhibitors are now in clinical trials for pancreatic cancer, addressing the genetic driver present in over 90% of cases.
This review covers the breakthrough development of KRAS inhibitors for pancreatic cancer, a disease where KRAS mutations drive over 90% of cases. Multiple therapeutic approaches including allele-specific inhibitors and pan-RAS agents are now in clinical trials with encouraging early results.
What the study was
- Study design
- Comprehensive review
- Population
- Pancreatic ductal adenocarcinoma patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Drug Design, Development and Therapy
Why it surfaced
Highly relevant review on KRAS targeting in PDAC from Mayo Clinic group. Review format caps design quality but content is timely and comprehensive.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.